These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7289414

  • 1. [O.p. DDD (lysodren) in treatment of adrenal cortex hyperfunction in childhood].
    Keller E, Willgerodt H, Teichmann B, Hoepffner W.
    Kinderarztl Prax; 1981 Aug; 49(8):436-41. PubMed ID: 7289414
    [No Abstract] [Full Text] [Related]

  • 2. [Formal pathogenesis, average age and breed distribution in the comparison of 61 Lysodren-treated and 36 untreated cases of canine hyperadrenocorticism which were dissected in the years 1975 to 1991 at the Institute for Veterinary Pathology of the Free University of Berlin].
    Nothelfer HB, Weinhold K.
    Berl Munch Tierarztl Wochenschr; 1992 Sep 01; 105(9):305-11. PubMed ID: 1417721
    [Abstract] [Full Text] [Related]

  • 3. [Medical therapy of hyperadrenalism].
    Raith L.
    Minerva Med; 1973 Mar 14; 64(14):682-4. PubMed ID: 4350585
    [No Abstract] [Full Text] [Related]

  • 4. [Use of mitotane (o,p'-DDD) in adrenal cortex hyperfunction].
    Kasperlik-Załuska A, Migdalska B.
    Endokrynol Pol; 1982 Mar 14; 33(1-3):99-104. PubMed ID: 7183447
    [No Abstract] [Full Text] [Related]

  • 5. [Associated role of surgery and antimitotic o, p'-DDD treatment in hyperfunctioning adrenal cancers with diffuse metastases].
    Perigli G, Borrelli D, Salvatore S, Cicchi P, Burci P.
    Chir Ital; 1981 Feb 14; 33(1):122-34. PubMed ID: 6167374
    [Abstract] [Full Text] [Related]

  • 6. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
    Randolph JF, Toomey J, Center SA, Scarlett JM, Reimers T, Graham P, Nachreiner RF.
    Am J Vet Res; 1998 Mar 14; 59(3):258-61. PubMed ID: 9522940
    [Abstract] [Full Text] [Related]

  • 7. [Further experience with the long-term treatment with aminoglutethimide in hyperfunction of the adrenal cortex (author's transl)].
    Marek J, Horký K, Gregorová I, Motlík K.
    Sb Lek; 1974 Aug 14; 76(7):200-13. PubMed ID: 4603552
    [No Abstract] [Full Text] [Related]

  • 8. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
    Reine NJ.
    Clin Tech Small Anim Pract; 2007 Feb 14; 22(1):18-25. PubMed ID: 17542193
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of glycoactive hypercorticism].
    Jacobelli A, Agostino A, Altomonte G.
    Clin Ter; 1984 Nov 30; 111(4):367-72. PubMed ID: 6098404
    [No Abstract] [Full Text] [Related]

  • 10. [Letter: Idiopathic hemochromatosis and Cushing's disease].
    Schrub JC, Courtois H.
    Nouv Presse Med; 1975 Mar 29; 4(13):972-3. PubMed ID: 1144042
    [No Abstract] [Full Text] [Related]

  • 11. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.
    Peterson ME, Kintzer PP.
    Vet Clin North Am Small Anim Pract; 1997 Mar 29; 27(2):255-72. PubMed ID: 9076906
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of Cushing's syndrome and adrenal cancer with O,p-DDD].
    Kinouchi T, Shimizu N, Ibayashi H, Demura H, Oshima H.
    Horumon To Rinsho; 1982 Aug 29; 30(8):841-51. PubMed ID: 7139984
    [No Abstract] [Full Text] [Related]

  • 13. [Recovery or remission of Cushing's disease following long term administration of OP'DDD in seventeen patients (author's transl)].
    Luton JP, Remy JM, Valcke JC, Laudat P, Bricaire H.
    Ann Endocrinol (Paris); 1973 Aug 29; 34(4):351-76. PubMed ID: 4360563
    [No Abstract] [Full Text] [Related]

  • 14. [Experiences with Lysodren treatment of Cushing's syndrome in dogs].
    Opitz M, Lettow E, Loppnow H, Grevel V.
    Tierarztl Prax; 1983 Aug 29; 11(4):507-20. PubMed ID: 6658774
    [No Abstract] [Full Text] [Related]

  • 15. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J, Droz JP.
    Bull Cancer; 2005 Mar 29; 92(3):273-9. PubMed ID: 15820922
    [Abstract] [Full Text] [Related]

  • 16. o,p'-DDD (mitotane) treatment of canine pituitary-dependent hyperadrenocorticism.
    Peterson ME.
    J Am Vet Med Assoc; 1983 Mar 01; 182(5):527-8. PubMed ID: 6300010
    [No Abstract] [Full Text] [Related]

  • 17. Effect of DL-2(p-aminophenyl)-2-phenylethylamine on adrenocortical function in Cushing's syndrome due to nontumorous adrenocrotical hyperfunction.
    Gabrilove JL, Nicolis GL, Gallagher TF.
    J Clin Endocrinol Metab; 1967 Nov 01; 27(11):1550-7. PubMed ID: 6075585
    [No Abstract] [Full Text] [Related]

  • 18. [Plasma determination of O,P-DDD. Clinical value].
    Leutenegger M, Caron J, Couchot J, Gross A, Maes B, Enger A, Millart H.
    Nouv Presse Med; 1977 Feb 19; 6(7):566. PubMed ID: 840640
    [No Abstract] [Full Text] [Related]

  • 19. [State of the skin in Itsenko-Cushing disease and hormonally active tumors of the adrenal cortex before and after treatment with chloditan].
    Mikhaĭlenko TI, Komissarenko IV.
    Vestn Dermatol Venerol; 1982 Aug 19; (8):64-6. PubMed ID: 7148138
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.